Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Mar 2, 2015
Insider Transaction Report
Form 4
Mirovsky Pavel
President of Valeant Europe
Transactions
- Exercise/Conversion
Common Stock, no par value
2015-02-27+10,000→ 10,000 total - Exercise/Conversion
Restricted Share Units
2015-02-27−10,000→ 10,000 totalExercise: $0.00→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $54.15 starting on May 15, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on February 15, 2015, 50% on May 15, 2015 and 25% on August 15, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value.
- [F2]Represents the maximum number of Common Shares that may be issued under the RSU award.